Literature DB >> 11044234

Glomerular permselectivity in early stages of overt diabetic nephropathy.

S Andersen1, K Blouch, J Bialek, M Deckert, H H Parving, B D Myers.   

Abstract

BACKGROUND: Impairment of glomerular size selectivity has been demonstrated by the dextran-sieving technique in nephropathic diabetics with heavy, but not mild proteinuria. The purpose of the present study was to determine whether such a barrier defect could be demonstrated with mild proteinuria by substituting Ficoll 70, a polysucrose, for dextran as a probe of the filtration barrier.
METHODS: Differential solute clearances were performed in 12 individuals with early diabetic nephropathy on two occasions: after 60 days of treatment with losartan 50 mg daily or a placebo. An uncharged preparation of nonreabsorbable Ficoll 70 was infused along with inulin. Fractional clearance (theta) of Ficoll of discrete size was determined after separating molecules in urine and plasma in narrow 2 A fractions over a 20 to 60 A radius interval by size exclusion high-performance liquid chromatography (HPLC). A hydrodynamic theory of hindered ficoll transport through water-filled pores was used to characterize the pore size distribution of the glomerular barrier.
RESULTS: The theta for Ficoll molecules with radii> 50 A was selectively enhanced in placebo-treated diabetic nephropathy versus corresponding theta in healthy control subjects (N = 12). Computations revealed a lower distribution of glomerular pores that was unaltered in nephropathic diabetics. However, an upper distribution of large, shunt-like pores was more prominent, exceeding healthy controls by one order of magnitude in diabetic nephropathy (P = 0.01). A trend to lower theta for Ficoll in the 56 to 60 A radius range during losartan therapy is computed to have lowered the fraction of shunted filtrate by 26 to 44%, depending on whether glomerular pressure declined. The corresponding reduction in theta for endogenous albumin, IgG, and IgG4 was by 19 to 23% (P < 0.05).
CONCLUSION: Our findings suggest that shunt-like defects, partially reversible by angiotensin II blockade, are present early in the course of diabetic nephropathy. We estimate that such defects can account for immunoglobulinuria in this disorder. Additional impairment of either charge- or shape-selectivity must be invoked to explain the observed level of albuminuria, however.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11044234     DOI: 10.1111/j.1523-1755.2000.00386.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  11 in total

1.  An Extended Minimal Physiologically Based Pharmacokinetic Model: Evaluation of Type II Diabetes Mellitus and Diabetic Nephropathy on Human IgG Pharmacokinetics in Rats.

Authors:  Gurkishan S Chadha; Marilyn E Morris
Journal:  AAPS J       Date:  2015-08-15       Impact factor: 4.009

Review 2.  Microalbuminuria in diabetes mellitus.

Authors:  Sheldon W Tobe; Philip Alan McFarlane; David Malcolm Naimark
Journal:  CMAJ       Date:  2002-09-03       Impact factor: 8.262

3.  Aliskiren in combination with losartan reduces albuminuria independent of baseline blood pressure in patients with type 2 diabetes and nephropathy.

Authors:  Frederik Persson; Julia B Lewis; Edmund J Lewis; Peter Rossing; Norman K Hollenberg; Hans-Henrik Parving
Journal:  Clin J Am Soc Nephrol       Date:  2011-02-24       Impact factor: 8.237

4.  Functional and molecular alterations of the glomerular barrier in long-term diabetes in mice.

Authors:  M Jeansson; A Björnson Granqvist; J Sörensson Nyström; B Haraldsson
Journal:  Diabetologia       Date:  2006-07-26       Impact factor: 10.122

5.  Urinary markers of glomerular injury in diabetic nephropathy.

Authors:  Abraham Cohen-Bucay; Gautham Viswanathan
Journal:  Int J Nephrol       Date:  2012-05-08

6.  Psammomys obesus, a particularly important animal model for the study of the human diabetic nephropathy.

Authors:  Pnina Scherzer; Shachaf Katalan; Gay Got; Galina Pizov; Irene Londono; Anca Gal-Moscovici; Mordecai M Popovtzer; Ehud Ziv; Moise Bendayan
Journal:  Anat Cell Biol       Date:  2011-09-29

7.  Mechanisms of glomerular albumin filtration and tubular reabsorption.

Authors:  Akihiro Tojo; Satoshi Kinugasa
Journal:  Int J Nephrol       Date:  2012-05-20

8.  Reduced glomerular size selectivity in late streptozotocin-induced diabetes in rats: application of a distributed two-pore model.

Authors:  Loay Lubbad; Carl M Öberg; Subramanian Dhanasekaran; Abderrahim Nemmar; Fayez Hammad; Javed Y Pathan; Bengt Rippe; Omran Bakoush
Journal:  Physiol Rep       Date:  2015-05

9.  Increased urine IgM excretion predicts cardiovascular events in patients with type 1 diabetes nephropathy.

Authors:  Rafid Tofik; Ole Torffvit; Bengt Rippe; Omran Bakoush
Journal:  BMC Med       Date:  2009-08-04       Impact factor: 8.775

10.  Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria.

Authors:  Frederik Persson; Peter Rossing; Henrik Reinhard; Tina Juhl; Coen D A Stehouwer; Casper Schalkwijk; A H Jan Danser; Frans Boomsma; Erik Frandsen; Hans-Henrik Parving
Journal:  Diabetes Care       Date:  2009-07-08       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.